Today the Supreme Court agreed to review the Myriad gene patenting case, Association
for Molecular Pathology v. Myriad Genetics. The case involved the patentability of
genes directed to detection of breast cancer (BRCA genes) and methods for using
them. The review is limited to question 1, which asks whether human genes are patentable. I previously wrote about the case here and here; SCOTUSblog's case page is here.
No comments:
Post a Comment